biostudies-literatureUnknown16(1)Uriot OIrritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder, with diarrhea-predominant IBS (IBS-D) as the most frequent subtype. The implication of gut microbiota in the disease's etiology is not fully understood. <i>In vitro</i> gut systems can offer a great alternative to <i>in vivo</i> assays in preclinical studies, but no model reproducing IBS-related dysbiotic microbiota has been developed. Thanks to a large literature review, a new Mucosal ARtifical COLon (M-ARCOL) adapted to IBS-D physicochemical and nutritional conditions was set-up. To validate the model and further exploit its potential in a mechanistic study, <i>in vitro</i> fermentations were performed using bioreactors inoculated with stools from healthy individuals (<i>n</i> = 4) or IBS-D patients (<i>n</i> =Bioengineered2458362https://www.ebi.ac.uk/biostudies/studies/S-EPMC11796540biostudies-literatureGut microbial dysbiosis associated to diarrheic irritable bowel syndrome can be efficiently simulated in the Mucosal ARtificial COLon (M-ARCOL).PMC11796540Scanzi JDapoigny MLangella PDeschamps CDurif CKerckhove NEtienne-Mesmin LDenis SBrun MFournier EDuale CUriot OAlric MStephanie BDfalseGut microbial dysbiosis associated to diarrheic irritable bowel syndrome can be efficiently simulated in the Mucosal ARtificial COLon (M-ARCOL).Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder, with diarrhea-predominant IBS (IBS-D) as the most frequent subtype. The implication of gut microbiota in the disease's etiology is not fully understood. <i>In vitro</i> gut systems can offer a great alternative to <i>in vivo</i> assays in preclinical studies, but no model reproducing IBS-related dysbiotic microbiota has been developed. Thanks to a large literature review, a new Mucosal ARtifical COLon (M-ARCOL) adapted to IBS-D physicochemical and nutritional conditions was set-up. To validate the model and further exploit its potential in a mechanistic study, <i>in vitro</i> fermentations were performed using bioreactors inoculated with stools from healthy individuals (<i>n</i> = 4) or IBS-D patients (<i>n</i> =2025-01-01T00:00:00Z2025 Dec2025-04-04T07:26:20.853Z2025-04-04T07:26:20.853ZS-EPMC117965403990288310.1080/21655979.2025.2458362